The 5 Peptides Every Newcomer Asks Me About (And Which Ones Actually Have Human Trials)
A pseudonymous reader walks through the five molecules that show up in my inbox more than any others, with the evidence grade for each one and an honest note on what newcomers tend to get wrong.
by JoyBoy
13 min read
Last reviewed May 2026
Mixed across 5 molecules
Mixed across 5 molecules
Why I looked into this
Most days, my inbox tells me the same story. New reader finds the site, reads one monograph, then asks a follow-up question about a peptide they heard about somewhere else. Five names dominate that traffic. The same five, over and over, in roughly the same order.
So I sat down and counted. I looked at six months of inbound questions, sorted by molecule, and ranked them by how often they came up. Then I lined up each one against the human evidence grade I would put on its own monograph, and I noticed something uncomfortable. The ranking by frequency does not match the ranking by evidence. Not even close.
This article is the answer I wish I could send back to every newcomer who asks me “what should I look at first?” The honest answer is: it depends what you mean by “look at.” If you mean “what is most asked about,” the list is below. If you mean “what has the strongest human research,” the list is partially the same and partially very different.
How I ranked these
The order is descending frequency from real reader questions over the last six months. Not survey data, not search volume, just what people email me about and what comes up in conversations on this site. I am one person reading one inbox, so this is my list, not the world’s. The order is still useful because the gaps it reveals are the gaps I see in the median newcomer’s understanding.
For each molecule below I give one paragraph on what it actually is, one paragraph on the human evidence with the grade, and one paragraph on the practical reality (FDA status, source-safety calculation, what the next step looks like). Each entry ends with a link to the full monograph if you want to read further.
1. The GLP-1 family (Semaglutide and Tirzepatide)
What are these?
Semaglutide and Tirzepatide are the two prescription GLP-1 family molecules dominating the conversation about weight management and metabolic health. Semaglutide is a single-receptor GLP-1 agonist, sold as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus in oral form. Tirzepatide is a dual-receptor agonist (GLP-1 plus GIP), sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The reason newcomers ask about these constantly is media saturation. Ozempic alone has been in the headlines for three straight years.
What does the human evidence show?
🟢 Human RCT Multiple Phase 3 programs, both molecules. Semaglutide’s STEP 1 trial (Wilding et al, NEJM 2021, n=1,961, industry funded by Novo Nordisk) showed roughly 14.9% mean weight loss at 68 weeks at the highest evaluated weekly amount. Tirzepatide’s SURMOUNT-1 trial (Jastreboff et al, NEJM 2022, n=2,539, industry funded by Eli Lilly) showed roughly 22.5% at 72 weeks. Semaglutide also has SELECT (Lincoff et al, NEJM 2023, n=17,604) showing about a 20% reduction in major adverse cardiovascular events, which led the FDA to add a cardiovascular indication to Wegovy in 2024. Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) reads out in the 2026 to 2027 window. The evidence base for this family is the strongest of any peptide on the site, by a wide margin.
What does a newcomer actually do with this?
For the GLP-1 family, the practical answer is the simplest of any peptide here. These are FDA-approved prescription drugs. The pathway is a clinician conversation, not a forum thread. The compounded shortcut that flooded the market during the 2022 to 2024 shortage window has largely lost its legal pathway, because the FDA moved both molecules off the shortage list in 2024 and 2025. The “research chemical copy at a tenth of the price” framing skips over what you are paying for at a licensed pharmacy: purity, sterility, and a real chain of custody. If you have heard about Ozempic and want to know what to do next, the answer is “talk to a clinician about whether the FDA-approved product is appropriate for your situation,” full stop.
Read the full Semaglutide monograph → · Read the full Tirzepatide monograph →
2. BPC-157
What is it?
BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice. It has been studied since the 1990s as a candidate for gastrointestinal and tendon-related applications. The forum reputation is enormous. Recovery, joint pain, gut healing, soft-tissue injury, every podcast that gets within ten feet of the topic mentions it. Newcomers ask about it more than any other single molecule on the site outside the GLP-1 family.
What does the human evidence show?
🔴 No Human Trials The honest answer is that there are no published randomized controlled trials of BPC-157 in humans, as of the May 2026 PubMed search I ran for the monograph. The reputation comes almost entirely from rodent work and from anecdote. Animal studies do not transfer cleanly to humans most of the time, and the peptides where animal data is most exciting are usually the ones where human data is thinnest. BPC-157 is the textbook example of that pattern. The FDA placed it on the docket FDA-2025-N-6895 for the July 23, 2026 PCAC review for ulcerative colitis, which is a meaningful regulatory step but not equivalent to approval. Advisory-committee inclusion does not equal approval and requires separate rulemaking.
What does a newcomer actually do with this?
The honest grade does the work here. If you are asking me about BPC-157 because of forum reputation, my response is to tell you the human evidence base does not exist yet. There are no FDA-approved BPC-157 products. The compounded gray market is vast, the labeling is often “research use only,” and the gap between the molecule on a vial label and the molecule in a published paper is real. If you decide it is worth the conversation anyway, the conversation is with a clinician who has actually read the literature, not with a forum. That conversation should start from “no human RCTs,” not from “everyone says it works.”
Read the full BPC-157 monograph →
3. Tesamorelin
What is it?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It causes the pituitary to release endogenous growth hormone, rather than supplying exogenous growth hormone the way HGH does. The FDA approved it in 2010 as Egrifta for HIV-associated lipodystrophy, specifically for excess visceral abdominal fat in that population. Newcomers ask about it as the “legitimate” answer to the HGH-alternative question they have been asking elsewhere.
What does the human evidence show?
🟢 Human RCT Multiple Phase 3 trials in HIV-associated lipodystrophy supported the FDA approval. Falutz et al (NEJM 2007, industry funded by Theratechnologies) showed meaningful reductions in visceral adipose tissue with corresponding changes in IGF-1. The Phase 3 program was sized appropriately for that indication. Outside of HIV-associated lipodystrophy, the human RCT evidence for general body composition or anti-aging applications is much thinner. The drug is approved for one specific population, and the off-label literature is not where the rigorous data lives.
What does a newcomer actually do with this?
Tesamorelin is the rare peptide where the FDA-approved product exists, the human RCTs are real, and the pathway is a prescription. The practical wrinkle is the indication mismatch. Egrifta is approved for HIV-associated lipodystrophy, not for general body composition. Off-label clinician decisions exist, and the 503A compounding pathway is more relevant here than for the GLP-1 family because the supply situation is different. Source-safety still applies fully. If you are asking about Tesamorelin because you read about GHRH analogs and want the cleanest evidence base in that category, this is the one. The conversation is still with a clinician who knows the labels and the indication.
Read the full Tesamorelin monograph →
4. PT-141 (Bremelanotide)
What is it?
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist developed for sexual dysfunction. The FDA approved it in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder. Newcomers ask about it because the off-label conversation around libido and sexual function pulls a lot of attention, and it is one of very few molecules in that conversation with an actual FDA approval and Phase 3 trial data behind it.
What does the human evidence show?
🟢 Human RCT The pivotal RECONNECT trials (Kingsberg et al, Obstet Gynecol 2019, industry funded by Palatin Technologies and AMAG Pharmaceuticals) supported approval in premenopausal women with hypoactive sexual desire disorder. Two identical Phase 3 trials, total n above 1,200, with the active arm showing modest but statistically significant improvements on the primary endpoints versus placebo. The effect sizes are real but not enormous, and the side effect profile (nausea, flushing, transient blood pressure changes) led to specific labeling. Male sexual function applications and the off-label conversation are less well supported by RCTs than the on-label indication.
What does a newcomer actually do with this?
Like Tesamorelin, the FDA-approved product exists and the pathway is a prescription. Vyleesi is approved for one specific indication. The off-label use is a clinician conversation, not a forum question. The thing newcomers tend to underestimate is the side effect profile (especially the transient blood pressure piece), which is on the label for a reason. If sexual function is the question driving the inquiry, the conversation should also include “are we looking at the right molecule for the right reason?” because the differential includes a long list of other contributors that have nothing to do with peptides.
Read the full PT-141 monograph →
5. Cerebrolysin
What is it?
Cerebrolysin is a porcine-brain-derived peptide preparation, developed in Austria and used clinically across Europe, Russia, and parts of Asia for stroke recovery, traumatic brain injury, and dementia indications. It is not a single defined peptide but a mixture of low-molecular-weight peptides and amino acids. Newcomers ask about it because it shows up in cognition and longevity conversations as the “legitimate” version of the smart-drug peptide question.
What does the human evidence show?
🟡 Human Observational with mixed-to-negative meta-analytic results. Cerebrolysin has been studied in humans for decades, with multiple RCTs across stroke, dementia, and TBI populations, but the Cochrane reviews tell a less flattering story than the marketing. The 2020 Cochrane review of Cerebrolysin in acute ischemic stroke (Ziganshina et al) concluded that the evidence does not support a beneficial effect on death or dependency, with ongoing concerns about study quality and potential bias. There are individual trials with positive findings, particularly in Eastern European literature, and the overall picture is “studied a lot, signal is messy, top-tier meta-analyses do not endorse routine use.”
What does a newcomer actually do with this?
Cerebrolysin is not FDA approved in the US. It is approved and marketed in many other countries. The cognition-and-longevity conversation that drives newcomer questions about it is mostly off-label even where the drug is approved. If you are reading about it because you want a cognition peptide with an evidence base, the honest framing is that the evidence base exists but the most rigorous reviews are not enthusiastic. The 503A pathway does not apply here because there is no FDA-approved version to compound from. Anyone selling you a US-distributed Cerebrolysin product outside a clinical trial is operating in a gray area, and the source-safety framework applies in full.
Read the full Cerebrolysin monograph →
FDA and legal status, summarized
FDA approved. Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound). Prescription only. Compounding pathway narrowed sharply in 2024 and 2025.
Not FDA approved. No human RCTs. On the docket FDA-2025-N-6895 for the July 23, 2026 PCAC review for ulcerative colitis. Advisory-committee inclusion is not approval and requires separate rulemaking.
Both FDA approved (Egrifta 2010 for HIV-associated lipodystrophy; Vyleesi 2019 for HSDD in premenopausal women). Prescription only. Off-label is a clinician conversation.
Not FDA approved in the US. Approved in many other countries. Cochrane reviews do not endorse routine use. No 503A pathway since no FDA-approved version exists to compound from.
I built a doctor visit-prep one-pager for the conversations newcomers most often need to have. Evidence summary, what to ask, what red flags to listen for. Free PDF. No upsell.
Get the visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- For Semaglutide, Tirzepatide, Tesamorelin, and PT-141: a real prescription from a clinician you can talk to, filled at a licensed pharmacy
- For BPC-157 and Cerebrolysin: enrollment in a clinical trial or, where applicable, a clinically supervised pathway in a country where the drug is approved
- Independent third-party testing of any compounded product, with the documentation actually shown to you
- A clinician who is willing to say “this is not a good fit for you” and walk away from the conversation
- Disclosure of where a compound is synthesized, who the prescribing clinician of record is, and what happens if you have a reaction
Red flags
- “Research use only” labeling on a vial that is being marketed for human use
- Anyone offering BPC-157 as a finished consumer product with claims of efficacy that the human RCT literature does not support
- Compounded GLP-1 products being marketed as if the 2023 era still applied
- Urgency or scarcity language (“last batch”, “before the FDA shuts it down”)
- Refusal to provide independent third-party lab testing, or testing from a lab that turns out to be the seller’s own affiliate
The wrinkle for this list specifically
The five molecules here split cleanly into two camps for source-safety purposes. The three FDA-approved ones (the GLP-1 family, Tesamorelin, PT-141) have a straightforward legitimate path: a prescription and a licensed pharmacy. The two unapproved ones (BPC-157, Cerebrolysin) do not have that path inside the US. The framework above applies to both camps, but the practical answer in the second camp is much narrower than the first. Anyone selling you a US-distributed version of an unapproved molecule outside a clinical trial is asking you to trust their lab work over the FDA’s, which may or may not be warranted, and most of the gray-market product on offer in 2026 cannot or will not show the testing required to find out.
Cost reality
List prices on the FDA-approved options are high, and insurance coverage is uneven. The compounded shortcut that drove the 2022 to 2024 conversation around Semaglutide and Tirzepatide has largely closed. The price gap that drove people toward research chemicals is real. The sterility-and-purity gap that comes with that path is also real. There is no free lunch in this transaction, and the cost calculation worth running is total cost of getting it right, not sticker price of the cheapest vial.
Questions worth asking any source
Where is this synthesized? Where is it independently tested, and can I see the documentation? Who is the prescribing clinician of record? What happens if I have a reaction? A real source has answers. A bad one has marketing copy.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of any of these peptides. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader and user. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
The thing that bothers me most about the newcomer pipeline is the inverse correlation. The molecule with the biggest forum reputation (BPC-157) has the thinnest human evidence. The molecules with the strongest human evidence (the GLP-1 family) are the ones the public is just now learning to take seriously, and only because they got branded as Ozempic and Wegovy in the first place. Forums create reputation independent of evidence. That is the mechanism, and it is not going to fix itself.
“Forum reputation and human-trial evidence are two different signals. They are correlated, weakly, in the wrong direction, for the molecules newcomers ask about most.”
For me, BPC-157 (paired with TB-500) coincided with a shoulder injury resolving over about a month. I cannot separate that from time, rest, and the fact that shoulders sometimes just recover. That experience belongs in the opinion section, not the evidence section, and I would not generalize it. For me, Retatrutide was a positive experience over a roughly four-week window earlier this year, but Retatrutide is not on this list because newcomers do not ask me about it yet. They will, soon, and the evidence base is genuinely strong (Phase 2 published, Phase 3 in progress). The five molecules on this list are the ones the median newcomer brings me in May 2026.
“The molecule with the biggest reputation has the thinnest human evidence. That gap is the whole reason this article exists.”
If a friend asked me “where should I start?” my answer would not be a peptide. It would be: read the evidence grade on whatever molecule you are curious about, before you read anything else. Then read the source-safety framework, before you talk to anyone trying to sell you anything. Then have the conversation with a clinician who knows your actual situation. The five molecules here are the five most-asked-about, not the five most-recommended. There is no recommendation in this article. There is only honest grading.
Questions to ask your doctor
If you are considering a conversation about any of these five, here is the order I would walk through the questions, regardless of which molecule prompted the appointment.
- Given my situation, is this molecule the right conversation at all? The five on this list serve completely different purposes. A clinician who knows your actual goals can tell you whether the molecule that brought you in is even the right starting point.
- What is the evidence grade you would put on this in humans? A clinician who has read the literature can answer this in one sentence. If they cannot, that is a useful signal in itself.
- Are we using the FDA-approved product, a compounded version, or something else? For the GLP-1 family, Tesamorelin, and PT-141, FDA-approved versions exist. For BPC-157 and Cerebrolysin in the US, they do not. The answer to this question shapes everything else.
- What is your stop condition, and what does monitoring look like? “We will check in” is not a plan. Specific markers, specific timelines, and a written line for “this is not working, here is what we change” are what you want.
- What side effects have you actually seen, in your practice, with this molecule? Phase 3 trial side effect profiles are public. What a clinician sees in their own patients is the second data source you cannot get from a paper.
- If I asked you to walk away because this is not appropriate, what would push you toward that answer? A clinician who can articulate the conditions under which they would say no is a clinician you want. A clinician who cannot is selling, not prescribing.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the individual monographs for whichever molecule on this list pulled you here. Each one walks the trial data in detail and grades the human evidence honestly.
Browse the monograph library →If you are considering
Have the conversation with a clinician you can actually reach. Bring the visit-prep packet. Bring your goals. Bring your stop condition before you start anything.
Get the visit-prep packet →If you have decided
Use the source-safety checklist before committing to any provider or pharmacy, especially given how the compounding rules changed in 2024 and 2025.
Download the source-safety checklist →Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Industry funded (Novo Nordisk).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. Industry funded (Eli Lilly).
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. Industry funded (Novo Nordisk).
- Falutz J, et al. Effects of tesamorelin on visceral fat and other adipose tissue depots. N Engl J Med. 2007;357:2359-2370. Industry funded (Theratechnologies).
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019. Industry funded (Palatin Technologies, AMAG Pharmaceuticals).
- Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020.
- US FDA. Wegovy, Zepbound, Egrifta, and Vyleesi prescribing information.
- US FDA docket FDA-2025-N-6895 (PCAC review of seven peptides, July 2026).
- PubMed search for “BPC-157” filtered for human clinical trials, May 2026: zero published RCTs.
Funding for the pivotal trials cited here is largely industry. That is worth saying plainly. Industry funding does not invalidate the data, but it is part of how the data should be read.
Related monographs
Semaglutide
The settled GLP-1 drug. Multiple Phase 3 programs and cardiovascular outcomes data.
BPC-157
The most-asked-about peptide on this list, with the thinnest human evidence base.
Tesamorelin
The GHRH analog with a real Phase 3 program and an FDA approval, in one specific population.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.